This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
GHRP-6 (2 mg Vial)
GHRP-6 (Growth Hormone-Releasing Peptide 6) is a synthetic hexapeptide that functions as a potent growth hormone secretagogue by binding to the ghrelin receptor (GHS-R1a)[1][2]. It stimulates pulsatile GH release from the pituitary gland while maintaining physiological feedback controls, resulting in elevated IGF-1 levels and potential anabolic benefits[3].
Quick Reference
What is GHRP-6?
Research overview based on the cited scientific literature.
• Goal: Stimulate pulsatile GH release to support muscle growth, fat loss, and recovery[2][7].
• Storage: Lyophilized frozen; reconstituted refrigerated; use within 7 days.
Storage Instructions
Proper storage preserves peptide quality and potency.
• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions with desiccant if available.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within 7 days[8].
• Avoid freeze-thaw cycles: Do not refreeze reconstituted solution; prepare aliquots if extended storage is needed.
• Allow vials to reach room temperature before opening to minimize condensation.
How is GHRP-6 studied?
GHRP-6 functions as a synthetic ghrelin mimetic by binding to the growth hormone secretagogue receptor (GHS-R1a) in the pituitary gland and hypothalamus[1][12]. This activation triggers acute, pulsatile growth hormone release from somatotroph cells while simultaneously reducing somatostatin’s inhibitory brake on GH secretion[3]. Unlike continuous GH administration, GHRP-6 maintains physiological feedback controls—as GH and IGF-1 levels rise, endogenous somatostatin increases to prevent excessive elevation, keeping GH pulses within normal physiologic ranges[5].
Beyond its endocrine effects, GHRP-6 exhibits cytoprotective properties through interactions with the CD36 receptor on immune and muscle cells[2][13]. This secondary pathway activates cell-survival signaling cascades (such as PI3K/Akt) that help protect tissues from oxidative stress and inflammation, explaining many of GHRP-6’s observed tissue-protective benefits in preclinical models including cardioprotection, neuroprotection, and anti-fibrotic effects[2][14].
What does the research report about GHRP-6?
Observations from clinical and preclinical literature.
Potential Benefits:
• Muscle Growth & Fat Loss: Elevated GH and IGF-1 levels support increased lean body mass and reduced fat mass over time[7][15].
• Enhanced Recovery: Improved sleep architecture (increased slow-wave sleep) and faster tissue repair[16].
• Appetite Stimulation: May increase hunger due to ghrelin receptor activation, potentially beneficial for weight gain goals[11].
• Tissue Protection: Preclinical studies show cytoprotective effects including reduced scar formation, cardioprotection, and neuroprotection[2][14][17].
• Joint & Connective Tissue Health: May support collagen synthesis and connective tissue repair through elevated IGF-1[7].
Potential Side Effects:
• Transient mild increases in cortisol and ACTH (typically not clinically significant)[18].
• Increased appetite and potential water retention.
• Occasional injection-site reactions (redness, itching, mild swelling).
• Possible transient dizziness or flushed feeling immediately after injection due to rapid GH spike.
• Generally well-tolerated in human trials at research doses with no major safety concerns reported[19].
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.
What are the limitations of the research on GHRP-6?
Evidence should be interpreted within the population, experimental model, formulation, route, outcome measures, and study design used in each cited source. Preclinical or early-stage findings do not establish clinical efficacy, safety, or approved human use. Where human evidence is available, results should not be generalized beyond the populations and conditions actually studied.